H	Heidelberg Pharma AG XMUN:HPHA	DE
	ON Semiconductor Corp NASDAQ:ON	US
	Emerita Resources Corp XTSX:EMO	CA
D	Daito Trust Construction Co Ltd SWB:4D7	JP
U	USANA Health Sciences Inc F:USJ	US
	Cadence Design Systems Inc NASDAQ:CDNS	US
S	Swire Pacific Ltd OTC:SWRAF	HK
	Eguana Technologies Inc XTSX:EGT	CA
	Valneva SE F:AYJ	FR
	Exelon Corp NASDAQ:EXC	US
F	Fomento Economico Mexicano SAB de CV F:FOMA	MX
S	Stellantis NV XMUN:8TI	NL
	Maeda Kosen Co Ltd TSE:7821	JP
	WEG SA BOVESPA:WEGE3	BR
A	Atlanta Braves Holdings Inc OTC:BATRB	US
	Vince Holding Corp NASDAQ:VNCE	US
A	Argan Inc F:1AW	US
	Adani Enterprises Ltd BSE:512599	IN
R	Regal Rexnord Corp F:RB8	US

Metric	FY2016 Nov 2016	FY2017 Nov 2017	FY2018 Nov 2018	FY2019 Nov 2019	FY2020 Nov 2020	FY2021 Nov 2021	FY2022 Nov 2022	FY2023 Nov 2023	FY2024 Nov 2024	FY2025 Nov 2025
Cash & Cash Equivalents	4.6m	30.4m	19.4m	9.9m	5m	6.1m	81.3m	43.4m	29.4m	15m
Cash Equivalents	4.6m	30.4m	19.4m	9.9m	5m	6.1m	81.3m	43.4m	29.4m	15m
Total Receivables	183.4k	494.4k	614.7k	1.4m	1.5m	1.4m	1.5m	2.3m	6m	2.3m
Accounts Receivables	91.3k	232.5k	366k	1.2m	1.2m	1m	1.1m	978.8k	283.9k	5.5k
Other Receivables	92k	261.9k	248.7k	178.7k	322.1k	429.6k	353.5k	1.3m	5.7m	2.3m
Inventory	190.2k	178k	177.6k	237.7k	229.8k	745.9k	4.6m	10.5m	11.8m	10.6m
Other Current Assets	41.9k	154.9k	56k	63.9k	799k	676.3k	513.3k	382.7k	375k	397.9k
Total Current Assets	5m	31.2m	20.3m	11.6m	7.5m	9m	87.9m	56.6m	47.6m	28.3m
PP&E Net	1.3m	1.3m	1.9m	2.4m	3.1m	3.7m	3.7m	3.8m	3.5m	912.1k
PP&E Gross	1.3m	1.3m	1.9m	2.4m	3.1m	3.7m	3.7m	3.8m	3.5m	912.1k
Accumulated Depreciation	(3m)	(3.4m)	(3.7m)	(4.2m)	(4.9m)	(5.5m)	(6.2m)	(7.1m)	(7.9m)	(8.7k)
Intangible Assets	2.8m	2.8m	2.8m	2.8m	2.8m	2.9m	2.8m	2.8m	2.7m	2.7m
Goodwill	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m
Note Receivable	15k	35k	25k	35k	30k	30k	30k	970k	30k	30k
Long-Term Investments	—	—	—	12.6k	0	0	—	—	—	—
Other Long-Term Assets	16.4k	16.4k	16.4k	9.9k	14.9k	4.9k	4.9k	4.8k	779.3k	36.1k
Other Assets	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m	6.1m
Total Assets	15.2m	41.5m	31.2m	23m	19.6m	21.7m	100.6m	70.4m	60.7m	38.1m
Accounts Payable	132.1k	1.5m	405.5k	1m	2.8m	903k	3.1m	7.9m	5.5m	7.2m
Accrued Liabilities	1.1m	1.7m	3.3m	3.4m	3.5m	3m	4m	1.2m	1.1m	911k
Short-Term Debt	3.7m	0	0	0	0	10.5m	15.8m	5.6m	0	0
Current Portion of Long-Term Debt	—	—	—	—	100.7k	91.1k	94.4k	113.2k	115.5k	101.8k
Other Current Liabilities	498k	1.3m	1.6m	2m	252.2k	491.3k	5m	5m	1.2m	3m
Deferred Revenue	100k	800k	1.6m	1.9m	252.1k	490.9k	5m	5m	1.2m	26.7k
Total Current Liabilities	5.5m	4.5m	5.3m	6.5m	6.6m	14.9m	27.9m	19.8m	8m	11.2m
Long-Term Debt	0	0	0	0	102k	75.6k	100.4k	70.4k	21.9m	36.8m
Other Liabilities	7.1k	8.8k	0	235.3k	0	23.4k	5.9m	1.2m	0	1.1m
Total Liabilities	5.5m	4.5m	5.3m	6.7m	6.7m	15m	33.9m	21m	29.9m	49.1m
Common Stock	12.9m	22.5m	28.1m	28.2m	31.1m	34.2m	46.6m	46.6m	46.6m	46.8m
Retained Earnings	(190.7m)	(201.6m)	(212.7m)	(222.3m)	(240.1m)	(265.5m)	(284.7m)	(302m)	(320.5m)	(362.7m)
Additional Paid In Capital	187.5m	216.1m	210.4m	210.4m	221.9m	238.1m	304.7m	304.8m	304.8m	305m
Other Equity	—	0	—	—	—	—	—	0	—	0
Total Equity	9.8m	37m	25.9m	16.3m	12.9m	6.7m	66.6m	49.3m	30.9m	(10.9m)
Total Liabilities & Equity	15.2m	41.5m	31.2m	23m	19.6m	21.7m	100.6m	70.4m	60.7m	38.1m
Common Shares Outstanding	13.5m	22.5m	28.1m	28.2m	31.1m	34.2m	46.6m	46.6m	46.6m	46.8m

Heidelberg Pharma AG XMUN:HPHA

A cash-generative biotech transitioning from legacy MS to acquired growth platforms

A global oncology platform moving from costly R&D expansion toward scalable profitability

A rapidly scaled RNAi platform moving from R&D losses to product profitability

A pre-commercial oncology platform funded by escalating losses and repeated capital raises

Continue HPHA Research

Company

Help

Tools

Stocks

Heidelberg Pharma AG
XMUN:HPHA